2017 Fiscal Year Final Research Report
Molecular biological profile of carcinoma in situ of urinary bladder as predictive and prognostic markers
| Project/Area Number |
15K10605
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
千原 良友 奈良県立医科大学, 医学部附属病院, 研究員 (40405395)
三宅 牧人 奈良県立医科大学, 医学部, 研究員 (80601400)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Keywords | 膀胱癌 / 上皮内癌 / 膀胱内注入療法 / CLDN / CXCL1 / Collagen / CD56 / 制御性T細胞 |
|---|
| Outline of Final Research Achievements |
Expression of OCT3/4 and CXCL1 is associated with BCG treatment failure of carcinoma in situ of the urinary bladder. Induction of CD4+、CD8+、CD56+、CD204+、Foxp3+ immune cells is also associated with BCG treatment outcomes of non-muscle invasive bladder cancer including carcinoma in situ. CLDN4 expression of cancer cells and CXCL1 in the tumor microenvironment is associated with recurrence, progression and drug resistance. Collagen type Ⅵα1 and collagen type ⅩⅢα1 expression in tumor budding site is associated with muscle invasion. A biomarker panel including IL8、MMP9、MMP10、angiogenin A、APOE、SDC1、A1AT、PAⅡ、CA9、and VEGF is a useful tool for predicting muscle invasive progression of carcinoma in situ.
|
| Free Research Field |
泌尿器腫瘍学
|
